What's in Alector Inc.'s pipeline?

Alector Inc. has 2 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Alector Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/alector-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Alector Inc. — Portfolio Competitive Intelligence Brief

Alector Inc. pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
AL003	AL003	marketed	TREM2 activator monoclonal antibody	TREM2	Neurology
AL001	AL001	phase 3	TREM2 agonist monoclonal antibody	TREM2	Neurology

Therapeutic area mix

Neurology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Alector Inc.:

Cite this brief

Drug Landscape (2026). Alector Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alector-inc. Accessed 2026-05-13.